Ascendis Pharma A/S ASND
252.68 USD +2.51 (+1.00%)
Nov 4, 2026, 12:05 PM EST
248.34 Day range 253.84
188.07 52-week range 282.15
- YTD
- +18.50%
- 1 year
- +21.34%
- Market cap
- 16.65B
- Revenue (ttm)
- 1.05B
- Profit margin
- 70.84%
- EPS (ttm)
- 13.12
- Shares out
- 65.80M
- P/E ratio
- 19.29
- Forward P/E
- 25.03
- YTD return
- +18.50%
- 1-year return
- +21.34%
- Volume
- 165.89K
- Avg volume
- 698.13K
- Open
- 252.50
- Previous close
- 250.17
- Day's range
- 248.34 – 253.84
- 52-week range
- 188.07 – 282.15
- Analysts
- Strong Buy
- Price target
- 305.02 (+20.7%)
- Earnings date
- Nov 11, 2026
YTD +37.40 (+17.53%)
Key statistics
- Enterprise value
- 15.99B
- PEG ratio
- 0.00
- Price / sales
- 15.72
- Price / book
- 10.18
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 114.70%
- Free cash flow
- 12.77M
- Total cash
- 812.26M
- Total debt
- 450.07M
- Return on equity
- 118.78%
- Short % of float
- 5.63%
- 50-day average
- 242.22
- 200-day average
- 238.27
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 305.02 +20.7% upside
Now 252.68
- Target (low)
- 261.81
- Target (mean)
- 305.02
- Target (high)
- 343.27
Ratings (0m) 21 20 buy · 1 hold · 0 sell
- Strong buy5
- Buy15
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate 1.12.
Financials — quick view
ASND Revenue — quarterly 339.29M
ASND Net income — quarterly 206.97M
ASND EPS — quarterly 3.22
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | 0.894 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | 1.71 | 3.29 | +1.58 | +92.40% |
| May 7, 2026 | Mar 31, 2026 | 0.1876 | 0.32 | +0.13 | +70.58% |
| Feb 11, 2026 | Dec 31, 2025 | -0.06 | -0.64 | -0.58 | -966.67% |
| Nov 12, 2025 | Sep 30, 2025 | -0.41 | -1.17 | -0.76 | -185.37% |
| Aug 7, 2025 | Jun 30, 2025 | -1.42 | -0.93 | +0.49 | +34.51% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 26, 2026 | Citigroup | main | Buy | Buy |
| Sep 25, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Sep 15, 2026 | Raymond James | down | Strong Buy | Outperform |
| Sep 2, 2026 | Oppenheimer | main | Outperform | Outperform |
| Sep 1, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 1, 2026 | Wedbush | reit | Outperform | Outperform |
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Website
- ascendispharma.com
News
Ascendis Pharma Reports Sustained Kidney Function Improvements Over 5-Years With TransCon PTH In Adults With Hypoparathyroidism 
TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years 
Ascendis Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Of European Medicines Agency For Marketing Authorization Of TransCon CNP In EU To Treat Achondroplasia 
Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children 
Here’s How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years 
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing 
Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026 
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today 
Ascendis Pharma A/S’s (ASND) “Overweight” Rating Reaffirmed at Cantor Fitzgerald 
Ascendis Pharma: Back To Full Independence
Your note
Sign in to keep a note on ASND — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIENAIME JEAN-JACQUES | Director | Purchase | Aug 13, 2026 | 2,900 |
| BODENHOFF MADS | Officer | Sale | Sep 7, 2026 | 0 |
| HOLTUG LARS | Director | Sale | Sep 1, 2026 | 4,000 |
| JENSEN FLEMMING STEEN | Officer | Sale | May 10, 2026 | 0 |
| SMITH SCOTT THOMAS | Chief Financial Officer | Purchase | Jun 1, 2026 | 4,367 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Massachusetts Financial Services Co. | 0.00% | 1,875,301 | 469.14M | Jun 29, 2026 |
| Blackrock Inc. | 0.00% | 2,211,833 | 553.33M | Jun 29, 2026 |
| Westfield Capital Management Co LP | 0.00% | 4,798,267 | 1.20B | Jun 29, 2026 |
| Capital International Investors | 0.00% | 1,988,614 | 497.49M | Jun 29, 2026 |
| FMR, LLC | 0.00% | 3,545,575 | 887.00M | Jun 29, 2026 |
| Artisan Partners Limited Partnership | 0.00% | 2,634,024 | 658.95M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Custodian Funds-FRANKLIN DYNATECH FUND | 0.00% | 1,000,000 | 250.17M | Jun 29, 2026 |
| JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund | 0.00% | 795,727 | 199.07M | Jun 29, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 0.00% | 639,106 | 159.89M | Jun 29, 2026 |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 0.00% | 3,364,767 | 841.76M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 0.00% | 1,099,854 | 275.15M | Jul 30, 2026 |
| American Century Mutual Funds, Inc.-ULTRA FUND | 0.00% | 664,000 | 166.11M | Jul 30, 2026 |